Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes

Summary

The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with or without a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.

Timeline

Start

2026-11-02

Primary completion

2028-09-04

Completion

2028-12-04

Drugs

Indications